Stockscreener 앱 받기
22.33
2.10%
-0.48
시간 외 거래:
22.60
0.27
+1.21%
전일 마감가:
$22.81
열려 있는:
$22.57
하루 거래량:
1.03M
Relative Volume:
0.86
시가총액:
$2.73B
수익:
$588.99M
순이익/손실:
$214.33M
주가수익비율:
13.26
EPS:
1.6844
순현금흐름:
$208.61M
1주 성능:
-4.53%
1개월 성능:
-8.56%
6개월 성능:
+12.89%
1년 성능:
-1.19%
1일 변동 폭
$22.20
$22.75
1주일 범위
$22.20
$23.57
52주 변동 폭
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.33 | 2.79B | 588.99M | 214.33M | 208.61M | 1.6844 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Analyst Upgrade: Is Catalyst Pharmaceuticals Inc a defensive stock2026 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
(CPRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Aug Rallies: Should I trade or invest in Catalyst Pharmaceuticals IncOptions Play & Community Verified Trade Signals - baoquankhu1.vn
Merger Talk: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Macro Moves & Weekly Setup with High ROI Potential - baoquankhu1.vn
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Offering Value After Strong Multi‑Year Share Price Gains - simplywall.st
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Weakness - Sahm
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics - MarketBeat
Fundsmith LLP Acquires 654,721 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
Kennedy Capital Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
EPS Watch: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
2025 results exceed expectations as 2026 outlook set, Catalyst Pharmaceuticals projects - Traders Union
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Fieldview Capital Management LLC - MarketBeat
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - Investing.com
Zacks.com featured highlights include Air Lease, National Energy, Catalyst and JBT Marel - The Globe and Mail
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Catalyst Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - TradingView
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Neo Ivy Capital Management Sells 104,411 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Intech Investment Management LLC Sells 46,656 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Raising Its 2026 Revenue Outlook And What’s Next - Sahm
Operating margin % of Catalyst Pharmaceuticals, Inc. – HAM:CN2 - TradingView
(CPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34% - Finviz
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - The Manila Times
Catalyst Pharmaceuticals to Present Real-World Findings on Duchenne Muscular Dystrophy at 2026 MDA Conference - Quiver Quantitative
American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - Bitget
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz
Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup - ChartMill
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Rafferty Asset Management LLC - MarketBeat
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - Finviz
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):